Cargando…

Obatoclax and LY3009120 Efficiently Overcome Vemurafenib Resistance in Differentiated Thyroid Cancer

Although the prognosis of differentiated thyroid cancer (DTC) is relatively good, 30-40% of patients with distant metastases develop resistance to radioactive iodine therapy due to tumor dedifferentiation. For DTC patients harboring BRAF(V600E) mutation, Vemurafenib, a BRAF kinase inhibitor, has dra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wei, Wei-Jun, Sun, Zhen-Kui, Shen, Chen-Tian, Song, Hong-Jun, Zhang, Xin-Yun, Qiu, Zhong-Ling, Luo, Quan-Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5381260/ https://www.ncbi.nlm.nih.gov/pubmed/28382170 http://dx.doi.org/10.7150/thno.17322

Ejemplares similares

LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer
por: Vakana, Eliza, et al.
Publicado: (2016)

Obatoclax and Paclitaxel Synergistically Induce Apoptosis and Overcome Paclitaxel Resistance in Urothelial Cancer Cells
por: Jiménez-Guerrero, Rocío, et al.
Publicado: (2018)

Stat3 targeted therapies overcome the acquired resistance to vemurafenib in melanomas
por: Liu, Fang, et al.
Publicado: (2013)

Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
por: Notarangelo, Tiziana, et al.
Publicado: (2017)

Obatoclax kills anaplastic thyroid cancer cells by inducing lysosome neutralization and necrosis
por: Champa, Devora, et al.
Publicado: (2016)

GX15-070 (obatoclax) overcomes glucocorticoid resistance in acute lymphoblastic leukemia through induction of apoptosis and autophagy
por: Heidari, N, et al.
Publicado: (2010)

Pharmacological inhibition of Ref-1 enhances the therapeutic sensitivity of papillary thyroid carcinoma to vemurafenib
por: Hu, Linfei, et al.
Publicado: (2022)

Diagnostic Performance of (18)F-FDG PET/CT in Papillary Thyroid Carcinoma with Negative (131)I-WBS at first Postablation, Negative Tg and Progressively Increased TgAb Level
por: Qiu, Zhong-Ling, et al.
Publicado: (2017)

Comparison of in vitro antileukemic activity of obatoclax and ABT-737
por: Opydo-Chanek, Małgorzata, et al.
Publicado: (2016)

Smac mimetic LCL161 overcomes protective ER stress induced by obatoclax, synergistically causing cell death in multiple myeloma
por: Ramakrishnan, Vijay, et al.
Publicado: (2016)

Early Combined SHP2 Targeting Reverses the Therapeutic Resistance of Vemurafenib in Thyroid Cancer
por: Ma, Weike, et al.
Publicado: (2023)

An evidence-based review of obatoclax mesylate in the treatment of hematological malignancies
por: Goard, Carolyn A, et al.
Publicado: (2013)

The BH3 Mimetic Obatoclax Accumulates in Lysosomes and Causes Their Alkalinization
por: Stamelos, Vasileios A., et al.
Publicado: (2016)

Novel Antiviral Activities of Obatoclax, Emetine, Niclosamide, Brequinar, and Homoharringtonine
por: Andersen, Petter I., et al.
Publicado: (2019)

The Bcl-2 inhibitor Obatoclax overcomes resistance to histone deacetylase inhibitors SAHA and LBH589 as radiosensitizers in patient-derived glioblastoma stem-like cells
por: Berghauser Pont, Lotte M.E., et al.
Publicado: (2014)

EGFR/uPAR interaction as druggable target to overcome vemurafenib acquired resistance in melanoma cells
por: Laurenzana, Anna, et al.
Publicado: (2019)

Obatoclax Rescues FUS-ALS Phenotypes in iPSC-Derived Neurons by Inducing Autophagy
por: Castillo Bautista, Cristina Marisol, et al.
Publicado: (2023)

Obatoclax impairs lysosomal function to block autophagy in cisplatin-sensitive and -resistant esophageal cancer cells
por: Yu, Le, et al.
Publicado: (2016)

Lung Metastases From Papillary Thyroid Cancer With Persistently Negative Thyroglobulin and Elevated Thyroglobulin Antibody Levels During Radioactive Iodine Treatment and Follow-Up: Long-Term Outcomes and Prognostic Indicators
por: Qiu, Zhong-Ling, et al.
Publicado: (2020)

Identification of anisomycin, prodigiosin and obatoclax as compounds with broad-spectrum anti-parasitic activity
por: Ehrenkaufer, Gretchen, et al.
Publicado: (2020)

Norcantharidin overcomes vemurafenib resistance in melanoma by inhibiting pentose phosphate pathway and lipogenesis via downregulating the mTOR pathway
por: Wang, Lei, et al.
Publicado: (2022)

Dual time-point (18)F-FDG PET/CT imaging with multiple metabolic parameters in the differential diagnosis of malignancy-suspected bone/joint lesions
por: Shen, Chen-Tian, et al.
Publicado: (2017)

miRNA-106a directly targeting RARB associates with the expression of Na(+)/I(−) symporter in thyroid cancer by regulating MAPK signaling pathway
por: Shen, Chen-Tian, et al.
Publicado: (2016)

The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma
por: Cui, Hongmei, et al.
Publicado: (2021)

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016)

mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib
por: Hanly, Elyse K., et al.
Publicado: (2015)

VCAM-1 Upregulation Contributes to Insensitivity of Vemurafenib in BRAF-Mutant Thyroid Cancer
por: Chen, Shitu, et al.
Publicado: (2020)

Interleukins in Thyroid Cancer: From Basic Researches to Applications in Clinical Practice
por: Xi, Chuang, et al.
Publicado: (2020)

Obatoclax induces Atg7-dependent autophagy independent of beclin-1 and BAX/BAK
por: McCoy, F, et al.
Publicado: (2010)

Obatoclax Regulates the Proliferation and Fusion of Osteoclast Precursors through the Inhibition of ERK Activation by RANKL
por: Oh, Ju Hee, et al.
Publicado: (2015)

Antimetastatic Properties of Prodigiosin and the BH3-Mimetic Obatoclax (GX15-070) in Melanoma
por: Espona-Fiedler, Margarita, et al.
Publicado: (2022)

Vemurafenib-resistance via de novo RBM genes mutations and chromosome 5 aberrations is overcome by combined therapy with palbociclib in thyroid carcinoma with BRAF(V600E)
por: Antonello, Zeus A., et al.
Publicado: (2017)

Long-Term Outcomes and Prognoses of Elderly Patients (≥65-Years-Old) With Distant Metastases From Well-Differentiated Thyroid Cancer During Radioiodine Therapy and Follow-Up
por: Qiu, Zhong-Ling, et al.
Publicado: (2021)

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
por: Lang, Matthias, et al.
Publicado: (2023)

RFX1–dependent activation of SHP-1 induces autophagy by a novel obatoclax derivative in hepatocellular carcinoma cells
por: Su, Jung-Chen, et al.
Publicado: (2014)

Scurvy in a patient on vemurafenib
por: Gerstenblith, Meg R., et al.
Publicado: (2014)

Ezrin Inhibition Overcomes Acquired Resistance to Vemurafenib in BRAFV600E-Mutated Colon Cancer and Melanoma Cells In Vitro
por: Car, Iris, et al.
Publicado: (2023)

Potential utility of the pan-Bcl-2 inhibitor GX15–070 (obatoclax) in cancer immunotherapy
por: Kim, Peter S, et al.
Publicado: (2014)

The pan-Bcl-2 inhibitor obatoclax promotes differentiation and apoptosis of acute myeloid leukemia cells
por: Opydo-Chanek, Małgorzata, et al.
Publicado: (2020)

Obatoclax reduces cell viability of acute myeloid leukemia cell lines independently of their sensitivity to venetoclax
por: Lima, Keli, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_e4sod3ohfmci79s578fbq17hpt